Chronic Drug-Induced Liver Injury: Updates and Future Challenges

Overview

Journal Front Pharmacol

Date 2021 Mar 25

PMID 33762948

Citations 13

Authors

Qiaoling Wang

Ang Huang

Jia-Bo Wang

Zhengsheng Zou

Affiliations

Soon will be listed here.

Abstract

Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing effective treatment. About 20% of patients with DILI develop into chronic DILI. Chronic DILI manifests as persistent or repeated inflammatory or diminishing bile ducts, even progresses to cirrhosis and needs liver transplantation eventually. However, research on chronic DILI over the last decades is still lacking, and the incidence, phenotypes, mechanisms, risk factors, and treatment have not been fully understood. In this paper, we reviewed the definition of chronic DILI, updated clinical studies in terms of incidence, special manifestations, and promising risk factors of chronic DILI, along with the recent progress and challenges in glucocorticoid therapy.

Citing Articles

Cefepime-Induced Mixed Hepatocellular and Cholestatic Liver Injury: A Case Report.

Toofantabrizi M, Timshina A, Dongol R Cureus. 2024; 16(11):e73393.

PMID: 39659312 PMC: 11631161. DOI: 10.7759/cureus.73393.

Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives.

Unagolla J, Das S, Flanagan R, Oehler M, Menon J Int J Pharm. 2024; 660:124381.

PMID: 38917958 PMC: 11246230. DOI: 10.1016/j.ijpharm.2024.124381.

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.

Mao Y, Ma S, Liu C, Liu X, Su M, Li D Hepatol Int. 2024; 18(2):384-419.

PMID: 38402364 DOI: 10.1007/s12072-023-10633-7.

Non-invasive differentiation of hepatic steatosis and steatohepatitis in a mouse model using nitroxyl radical as an MRI-contrast agent.

Yoshino Y, Fujii Y, Chihara K, Nakae A, Enmi J, Yoshioka Y Toxicol Rep. 2024; 12:1-9.

PMID: 38173653 PMC: 10758964. DOI: 10.1016/j.toxrep.2023.12.002.

Highlighting the Use of the Hepatoprotective Nutritional Supplements among Patients with Chronic Diseases.

Foghis M, Tit D, Bungau S, Ghitea T, Pallag C, Foghis A Healthcare (Basel). 2023; 11(19).

PMID: 37830722 PMC: 10572698. DOI: 10.3390/healthcare11192685.

References

Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M . Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005; 330(7497):932. PMC: 556336. DOI: 10.1136/bmj.38391.663287.E0. View

Martinez-Casas O, Diaz-Ramirez G, Marin-Zuluaga J, Munoz-Maya O, Santos O, Donado-Gomez J . Differential characteristics in drug-induced autoimmune hepatitis. JGH Open. 2018; 2(3):97-104. PMC: 6207017. DOI: 10.1002/jgh3.12054. View

Xie W, Wang Q, Gao Y, Pan C . Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report. BMC Gastroenterol. 2018; 18(1):142. PMC: 6162916. DOI: 10.1186/s12876-018-0869-9. View

Fontana R, Hayashi P, Gu J, Reddy K, Barnhart H, Watkins P . Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014; 147(1):96-108.e4. PMC: 4285559. DOI: 10.1053/j.gastro.2014.03.045. View

Chalasani N, Hayashi P, Bonkovsky H, Navarro V, Lee W, Fontana R . ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109(7):950-66. DOI: 10.1038/ajg.2014.131. View

Martinez-Odriozola P, Gutierrez-Macias A, Ibarmia-Lahuerta J, Munoz-Sanchez J . Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig Dis Sci. 2009; 55(4):1191-2. DOI: 10.1007/s10620-009-0805-5. View

Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M . Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019; 156(8):2230-2241.e11. DOI: 10.1053/j.gastro.2019.02.002. View

Li L, Zheng S, Chen Y . Stevens-Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. J Int Med Res. 2019; 47(9):4537-4543. PMC: 6753534. DOI: 10.1177/0300060519868594. View

Suzuki A, Barnhart H, Gu J, Bonkovsky H, Tillmann H, Fontana R . Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int. 2017; 37(11):1723-1730. PMC: 5545077. DOI: 10.1111/liv.13380. View

10.

Patel V, Sanyal A . Drug-induced steatohepatitis. Clin Liver Dis. 2013; 17(4):533-46, vii. PMC: 4888072. DOI: 10.1016/j.cld.2013.07.012. View

11.

Abugroun A, Garcia I, Ahmed F, Potts S, Flicker M . The first report of atovaquone/proguanil-induced vanishing bile duct syndrome: Case report and mini-review. Travel Med Infect Dis. 2019; 32:101439. DOI: 10.1016/j.tmaid.2019.06.010. View

12.

Lin G, Wang J, Li N, Li M, Gao H, Ji Y . Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2010; 54(4):666-73. DOI: 10.1016/j.jhep.2010.07.031. View

13.

Nicoletti P, Aithal G, Bjornsson E, Andrade R, Sawle A, Arrese M . Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology. 2017; 152(5):1078-1089. PMC: 5367948. DOI: 10.1053/j.gastro.2016.12.016. View

14.

Aithal G, Ramsay L, Daly A, Sonchit N, Leathart J, Alexander G . Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004; 39(5):1430-40. DOI: 10.1002/hep.20205. View

15.

Kan M, Himes B . Insights into glucocorticoid responses derived from omics studies. Pharmacol Ther. 2020; 218:107674. PMC: 7854977. DOI: 10.1016/j.pharmthera.2020.107674. View

16.

Wang F, Fan J, Zhang Z, Gao B, Wang H . The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(6):2099-108. PMC: 4867229. DOI: 10.1002/hep.27406. View

17.

George N, Chen M, Yuen N, Hunt C, Suzuki A . Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul Toxicol Pharmacol. 2018; 94:101-107. DOI: 10.1016/j.yrtph.2018.01.018. View

18.

Dash A, Figler R, Sanyal A, Wamhoff B . Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol. 2016; 13(2):193-204. PMC: 7288748. DOI: 10.1080/17425255.2017.1246534. View

19.

Licata A, Maida M, Cabibi D, Butera G, Macaluso F, Alessi N . Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis. 2014; 46(12):1116-20. DOI: 10.1016/j.dld.2014.08.040. View

20.

Flynn J, Demling R . Inhibition of endogenous thromboxane synthesis by exogenous prostacyclin during endotoxemia in conscious sheep. Adv Shock Res. 1982; 7:199-207. View